Category: drug design

Eye researcher loses fourth paper for misconduct following Georgia, VA investigation

Azza B. El-Remessy
Azza B. El-Remessy

A biologist at the University of Georgia has lost a paper after an investigation revealed she had tampered with three images.

In 2014, Azza El-Remessy notched three retractions for a series of image errors. Now, a fourth retraction notice, and an expression of concern, explain there has been an investigation into her work. The investigation — conducted by two Georgia institutions, along with the Charlie Norwood Veterans Affairs Medical Center, where El-Remessy has additional appointments — has found evidence of misconduct.

The retraction notice for “Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration” explains:

Continue reading Eye researcher loses fourth paper for misconduct following Georgia, VA investigation

Amid controversial Sarepta approval decision, FDA head calls for key study retraction

FDAThe head of the U.S. Food and Drug Administration (FDA) has called for the retraction of a study about a drug that the agency itself approved earlier this week, despite senior staff opposing the approval.

On September 19, the FDA okayed eteplirsen to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder that results in muscle degeneration and premature death. Several of its top officials disagreed with the drug’s approval, questioning how beneficial it will be for patients, as Forbes, MedPage Today and others reported.

In a lengthy report Commissioner Robert Califf sent to senior FDA officials on September 16 — that was made public on September 19 — he called for the retraction of a 2013 study published in Annals of Neurology funded by the seller of eteplirsen, which showed beneficial effects of the drug in DMD patients. Califf writes in the report:

Continue reading Amid controversial Sarepta approval decision, FDA head calls for key study retraction

U Colorado’s former “golden boy” up to 7 retractions

University of Colorado DenverA former graduate student at the University of Colorado Denver has gained three retractions and two expressions of concern (EOC), following an institutional probe into his work. 

Last year, we reported on an investigation by the University of Colorado Denver into the research of Rajendra Kadam, which recommended retracting 10 papers. The report also flagged eight additional papers co-authored by Kadam whose data could not be validated, raising “concerns as to the scientific validity and integrity” of the material. A few months later, we reported on some of the notices — four retractions and an EOC — that had begun to appear for Kadam’s manuscripts.

We’ve since discovered more notices, bringing his total to seven retractions and three EOCs. 

Kadam was once a prominent member in the lab of Uday Kompella, and often referred to by colleagues as the “golden boy,” according to the institution’s report. In 2012, he won a graduate student symposium award from the American Association of Pharmaceutical Scientists.

A University of Colorado Denver spokesperson told Retraction Watch: Continue reading U Colorado’s former “golden boy” up to 7 retractions

7th retraction for Ohio researcher who manipulated dozens of figures

Terry Elton, via OSU
Terry Elton

A pharmacology researcher at Ohio State University has added his seventh retraction, four years after a finding of misconduct by the U.S. Office of Integrity (ORI).

An analysis of the work of Terry Elton determined that he had

falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers.

 In 2012, the ORI finding, which resulted in a three-year funding ban (that is now complete), recommended that Elton retract all six papers, one of which had already been retracted at the time of the report. 

Four years later, the last of the six papers flagged by the ORI has finally been retracted by Molecular and Cellular Endocrinology.

Here’s the retraction notice: Continue reading 7th retraction for Ohio researcher who manipulated dozens of figures

Does dose matter? Tumor killer paper thought so, now must retract

Molecular Medicine ReportsAfter questions from a reader, researchers took a second look at their data about the effects of a vitamin A metabolite on tumor cells, and realized their key finding was inaccurate.

They’re now retracting the paper, from Molecular Medicine Reports, because it originally reported that higher concentrations of retinoic acid (RA) were more effective in curbing the proliferation of brain tumor cells. But it seems that the RA dose made less of a difference than they originally believed, according to the retraction notice:

Continue reading Does dose matter? Tumor killer paper thought so, now must retract

You’ve been dupe’d: Results so nice, journals published them twice

With so many retraction notices pouring in, from time to time we compile a handful of straight-forward retractions.

Once again, this list focuses on duplications — but unlike other duplications, these authors were not at fault. Rather, these retractions occurred because the publishers mistakenly published the same paper twice — the result of a transfer between publishers, for instance, or accidentally publishing the unedited version of the paper. We’re forced to wonder, as we have before, whether saddling researchers’ CVs with a retraction is really the most fair way to handle these cases.

So without further ado, here’s five cases where the journal mistakenly duplicated a paper, and had to retract one version: Continue reading You’ve been dupe’d: Results so nice, journals published them twice

Seven retractions for prominent cancer researcher brings total to 18

Bharat Aggarwal
Bharat Aggarwal

A cancer researcher has earned seven more retractions following an investigation into his work by his former employer, MD Anderson Cancer Center in Texas, bringing his total to 18 retractions.

Bharat Aggarwal‘s name will be familiar to some readers, as he has threatened to sue Retraction Watch for reporting on his case.

All of the new retraction notices, issued by The Journal of Biological Chemistry (JBC), stem from image-related issues. The now-retired Aggarwal has seven papers that have each been cited at least 1,000 times, and in 2015, he was on Thomson Reuters Web of Science’s list of The World’s Most Influential Scientific Minds. With these new notices, he also has made it to our leaderboard of individual researchers who’ve racked up the most retractions.

An MD Anderson spokesperson sent us this statement: Continue reading Seven retractions for prominent cancer researcher brings total to 18

PhD student expelled for submitting paper without co-authors’ consent

PLOS OneA PhD student has been expelled from a university in China after publishing a paper in PLOS ONE without the permission of her co-authors, and using an external company to complete some of the work. 

PLOS ONE has now retracted the paper, noting that they were tipped off to the problems by a reader who raised concerns about some of the figures. The notice states that the study’s first author, Zhenni Zhang, takes full responsibility. 

The last author of the paper — Zongfang Li from the Xi’an Jiaotong University in China — told us Zhang was his PhD student who was close to completing her PhD, but has now been expelled.

Here’s the retraction notice, issued on July 25: Continue reading PhD student expelled for submitting paper without co-authors’ consent

Ex-Mount Sinai postdoc who falsified 50+ images earns 5-year funding ban

ori-logoA former postdoctoral researcher at the Mount Sinai School of Medicine in New York has received a five-year funding ban after an investigation concluded that they had falsified data underlying more than 50 images.

According to a report released today by the Office of Research Integrity (ORI), Zhiyu Li falsified Continue reading Ex-Mount Sinai postdoc who falsified 50+ images earns 5-year funding ban

Authors retract PNAS paper suggesting silk stabilizes vaccines

PNASA PNAS paper that caught the media’s attention for suggesting that adding silk could stabilize vaccines and antibiotics has been pulled after the authors realized there were significant errors in the data analysis. 

According to the notice, the authors agreed to retract the 2012 paper; however, the corresponding author told us the authors did not think a retraction was required as, according to him, the conclusions remained valid.

The paper presented a solution to the long-standing problem that sensitive biological compounds such as vaccines and antibiotics begin to lose their effectiveness outside the recommended temperature range, and naturally biodegrade over time. The degradation process cannot be reversed, and may even speed up during transport or storage under less ideal temperatures.

Here’s the retraction notice: Continue reading Authors retract PNAS paper suggesting silk stabilizes vaccines